Patents by Inventor Renaud Geslain

Renaud Geslain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Screening method for identifying new aminoacyl-tRNA synthetase inhibitors
    Patent number: 8183006
    Abstract: The method comprising: a) obtaining a gene sequence codifying a naturally occurring aminoacyl-tRNA synthetase; b) engineering the gene codifying for said aminoacyl-tRNA synthetase, resulting into an aminoacyl-tRNA synthetase with a defective activity, with the proviso that the engineering does not affect the functionality of the catalytic site of the enzyme; c) cloning the gene resulting from step (b) in an expression vector; d) transforming isolated mammalian cells with the expression vector resulting from step (c); e) growing the recombinant cells resulting from step (d) in a nutrient medium under conditions which allow the expression of the engineered aminoacyl-tRNA synthetase, resulting the expression into cell death or a decrease in the rate of cell division; f) providing a substance to be tested to the medium resulting from step (e); and g) analyzing the resulting cell growth, wherein if there is an increase in cell growth, then the substance selectively inhibits the activity of the engineered aminoacyl
    Type: Grant
    Filed: August 30, 2007
    Date of Patent: May 22, 2012
    Assignees: Fundacio Privada Parc Cientific de Barcelona, Institucio Catalana de Recerca I Estudis Avanca
    Inventors: Lluis Ribas De Pouplana, Teresa Bori Sanz, Manuel Castro De Moura, Renaud Geslain
  • Screening method for identifying new aminoacyl-tRNA synthetase inhibitors
    Publication number: 20100055719
    Abstract: The method comprising: a) obtaining a gene sequence codifying a naturally occurring aminoacyl-tRNA synthetase; b) engineering the gene codifying for said aminoacyl-tRNA synthetase, resulting into an aminoacyl-tRNA synthetase with a defective activity, with the proviso that the engineering does not affect the functionality of the catalytic site of the enzyme; c) cloning the gene resulting from step (b) in an expression vector; d) transforming isolated mammalian cells with the expression vector resulting from step (c); e) growing the recombinant cells resulting from step (d) in a nutrient medium under conditions which allow the expression of the engineered aminoacyl-tRNA synthetase, resulting the expression into cell death or a decrease in the rate of cell division; f) providing a substance to be tested to the medium resulting from step (e); and g) analyzing the resulting cell growth, wherein if there is an increase in cell growth, then the substance selectively inhibits the activity of the engineered aminoacyl
    Type: Application
    Filed: August 30, 2007
    Publication date: March 4, 2010
    Applicants: Fundacio Privada Parc Cientific De Barcelona, Fundacio Privada Institut De Recerca Biomedica, Institucio Catalana De Recerca I Estudis Avancats
    Inventors: Lluis Ribas De Pouplana, Teresa Bori Sanz, Manuel Castro De Moura, Renaud Geslain